OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


Staging and Grading

In order to make a definitive diagnosis of ovarian cancer, a gynecologic oncologist must perform surgery to gather samples for analysis by a pathologist. During the surgery, the surgeon will assess how far the disease has spread. This assessment is called “staging.” Along with grading (see below), these assessments help your doctor recommend a treatment plan.

Staging in ovarian cancer and other gynecologic cancers has been standardized by the International Federation of Gynecology and Obstetrics (FIGO). While other factors impact prognosis, FIGO stage is by far the most important predictor of long term survival.

For more detailed information on ovarian cancer diagnosis by stage, please see below.

Cancer Grading
By looking at the cells in the tissue and fluid under a microscope, a pathologist describes the cancer as Grade 1, 2, or 3. Grade 1 is most like ovarian tissue and less likely to spread; Grade 3 cells are more irregular and more likely to metastasize. However, many ovarian cancers are categorized simply as “low grade” or “high grade.” Chemotherapy is often not used to treat low grade Stage I cases.

Your Name (required)

Your Email (required)

Zip Code